BioSpace News Archive

Orca Bio, a clinical-stage biotechnology company, today announced that preliminary data from the Phase I/II clinical trials of Orca-T (NCT04013685 and NCT01660607) will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting, to be held virtually from December 5-8, 2020.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that four abstracts – including one oral presentation and three poster presentations – have been accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting taking place December 5-8, 2020.

Abcam’s new premium-grade bioactive proteins are highly-active growth factors and cytokines manufactured and designed to meet the specific needs of cell culture, including cell and gene therapy and regenerative medicine.

Results from five-year PROUD-PV/CONTINUATION-PV studies in rare blood cancer featured as oral presentation

MacroGenics, Inc. announced six clinical and preclinical abstracts related to acute myeloid leukemia and flotetuzumab, an investigational bispecific CD123 × CD3 DART® molecule, and one abstract related to tebotelimab, an investigational bispecific PD-1 × LAG-3 DART molecule, to be presented at the 62nd American Society of Hematology Annual Meeting & Exposition, December 5-8, 2020.

Ongoing manufacturing improvements shows enhanced efficacy of ARU-1801 for the treatment of sickle cell disease

Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting Long-Term Use of Oxbryta® (voxelotor)

Prothena Corporation plc, a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, reported financial results for the third quarter and first nine months of 2020.

New Drug Application (NDA) for trilaciclib in small cell lung cancer accepted for Priority Review with a PDUFA action date of February 15, 2021

Trevi Therapeutics, Inc. announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 11, 2020, to provide a corporate update and review the Company’s financial results for the third quarter ended September 30, 2020.